FDA Drug Detention Regulation Follows Devices Oversight Model
This article was originally published in The Tan Sheet
Executive Summary
A proposed rule implementing new FDASIA authority to administratively detain drugs believed to be adulterated or misbranded largely mirrors regulations already in place for medical devices, FDA says.